Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. demonstrates a positive outlook fueled by the anticipated growth of Xphozah's contributions, supported by strategic investments in its patient assistance program and sales efforts. The revenue forecasts for IBSRELA have been revised upward, with projected figures of $422 million for FY26 and $878 million for FY29, reflecting strong market demand and effective prescription uptake. Clinical evidence showcases significant improvements in patient outcomes, particularly for those with severe constipation, which underscores the therapeutic efficacy of Ardelyx's offerings and enhances the company’s market position.

Bears say

Ardelyx Inc's financial outlook is negatively impacted by a decrease in gross-to-net (GTN) margins for its product Ibsrela, which fell to 31% in 3Q25 from 32.2% in 2Q25, reflecting potential pricing pressures. Additionally, despite promising clinical results for Xphozah in serum phosphate reduction, changes to reimbursement pricing structures could hurt the overall revenue potential for both products. Furthermore, the company's guidance for peak net sales exceeding $1 billion for Ibsrela appears unattainable, particularly if it fails to secure critical product labeling features necessary for market competitiveness.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.